Effective Sales and Marketing Strategies for Orphan Drugs

NEW YORK, July 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Effective Sales and Marketing Strategies for Orphan Drugs

http://www.reportlinker.com/p0939704/Effective-Sales-and-Marketing-Strategies-for-Orphan-Drugs.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

The real potential for orphan drug pharma marketing

With drug pipelines moving from essential products to niche therapies, large pharma companies are increasingly attracted to the prospective high demand and low competition of orphan drug markets. However, the 'sales and marketing' models for orphan drugs are distinctly different to conventional models for common medications. So the transition to this specialist field is a lot more challenging than it appears.

A new report from FirstWord Dossier Effective Sales and Marketing Strategies for Orphan Drugs examines the effectiveness of strategic business models that big pharma are using to market these products. It draws upon the in-depth opinions of 13 experts from the orphan drugs industry, patient organisations, and regulatory authorities in rare diseases.

Report Overview

Effective Sales and Marketing Strategies for Orphan Drugs summarises the main issues, challenges and tactics involved in launching new pharma products for rare diseases. The report compares the critical differences between marketing orphan vs non-orphan drugs from initial drug development through to commercialisation. It also discusses the huge potential of this field and the key factors driving new product awareness and approval.

Key Report Features

Overview of pharma's current role in the rare diseases market

Originally posted here:
Effective Sales and Marketing Strategies for Orphan Drugs